- Therapy response prediction to immuno-oncology drugs in ovarian cancer
- IO-Resp is a 2cureX project financed by a 780.000 EUR grant from the “SME-innovative – medical technology” Program of the German Federal Ministry of Education and Research. The IO-Resp objective is to expand the ability of 2cureX’s IndiTreat® test so that it can predict the responses to immune-oncology drugs.
- IO-Resp started in April 2020 and will run for 36 month.
- Partner to the IO-Resp project is the University medical center Hamburg Eppendorf (UKE). The Department of Gynecology and the Acute Leukemia Lab of the Department of Oncology provide expertise in novel drug therapy approaches for the treatment of ovarian cancer patients. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.
- The funds ensure that the assay principle underlying the functional precision medicine test developed by 2cureX can be adapted so that IndiTreat® can be used to pre-therapeutically measure an ovarian cancer patient’s sensitivity to various check-point inhibitors. In addition it supports establishing a R&D presence in the fields of drug sensitivity testing immuno-oncology and ovarian cancer.
IO-Resp Grant agreement
1 April 2020
SME-innovative – medical technology
December 7, 2021
CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)
December 9, 2021
2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)
January 20, 2022
2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)
February 24, 2022
Year-End Report 2021